BCRP

Breast cancer resistance protein;ABCG2



BCRP(breast cancer resistant protein) is an ATP-binding cassette (ABC) transporter, which together with two other ABC efflux drug pumps, namely P-glycoprotein (P-gp, ABCB1) and multidrug resistance-related protein 1 (MRP1, ABCC1) is the most important multidrug resistance protein found in eukaryotic cells including cells in the testis.

Breast cancer resistance protein (BCRP/ABCG2) is known to localize at the blood-brain barrier (BBB) and can significantly restrict xenobiotic permeability in the brain. The objective of this study is to investigate the regulation of BCRP functional expression by peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor primarily involved in lipid metabolism, in a cerebral microvascular endothelial cell culture system (hCMEC/D3), representative of human BBB.

BCRP Inhibitors & Modulators

BCRP-IN-1

Cat. No.: HY-100390

Bioactivity: BCRP-IN-1 is a breast cancer resistance protein (**BCRP**) inhibitor with an **IC_{50}** of 0.6 μM on BCRP efflux transporter.

Purity: 98.13%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Elacridar

(GF120918; GW0918; GG918; GW120918)

Cat. No.: HY-50879

Bioactivity: Elacridar is a potent **P-glycoprotein (Pgp)** and **BCRP** inhibitor.

Purity: 98.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Fumitremorgin C

(12α-Fumitremorgin C)

Cat. No.: HY-N2143

Bioactivity: Fumitremorgin C is a potent and selective **ABCG2/BRCP** inhibitor.

Purity: 99.63%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
250u g, 1 mg



Ko 143

Cat. No.: HY-10010

Bioactivity: Ko 143 is a potent and selective ATP-binding cassette sub-family G member 2 (**ABCG2**) inhibitor.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



KS176

Cat. No.: HY-19753

Bioactivity: KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.

Purity: 99.21%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



YHO-13177

Cat. No.: HY-12757

Bioactivity: YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells.

Purity: 98.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



YHO-13351

Cat. No.: HY-12758

Bioactivity: YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



YHO-13351 free base

Cat. No.: HY-12758A

Bioactivity: YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.

Purity: 98.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Zamicastat

(BIA 5-1058)

Cat. No.: HY-106004

Bioactivity: Zamicastat (BIA 5-1058) is a **dopamine β-hydroxylase (DBH)** inhibitor that could cross the blood-brain barrier (BBB) and cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dual **P-gp** and **BCRP** inhibitor with **IC_{50}** values of 73.8 μM and 17.0 μM, respectively [1]....

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg